Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Rhea-AI Summary

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, has scheduled its Q1 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.

Participants must pre-register for the conference call through a provided link. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.

BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform^® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.

Contact:

Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com

FAQ

When will Lisata Therapeutics (LSTA) report Q1 2025 earnings?

Lisata Therapeutics will report Q1 2025 earnings on Thursday, May 8, 2025, after market close.

What time is Lisata Therapeutics' (LSTA) Q1 2025 earnings call?

Lisata Therapeutics' Q1 2025 earnings conference call is scheduled for 4:30 p.m. Eastern time on May 8, 2025.

How can I access Lisata Therapeutics' (LSTA) Q1 2025 earnings call?

Participants must pre-register through a provided link to receive dial-in details. A live webcast will also be available on Lisata's website under the Investors & News section.

How long will Lisata Therapeutics' (LSTA) Q1 2025 earnings call replay be available?

The earnings call replay will be available for 12 months following the call on Lisata's website.